Table 1.
Demographic data and tumor characteristics of the 2473 Patients
| N = 2473 | N (%), MEANS ± SD |
|---|---|
| Age, Y | 54.0 ± 11.2 |
| Location | |
| Right | 1194 (48.3) |
| Left | 1279 (51.7) |
| Biopsy method (N/A = 37) | |
| Us-guided core needle biopsy | 2302 (94.5) |
| Stereotactic vacuum-assisted biopsy | 53 (2.2) |
| Excisional biopsy | 72 (3.0) |
| Fine needle aspiration | 5 (0.2) |
| Stereotactic core needle biopsy | 4 (0.2) |
| Tumor size, cm | 2.3 (1.6) |
| Lymph node | |
| Positive | 861 (34.8) |
| Negative | 1612 (65.2) |
| Lymph node stage | |
| N0 | 1612 (65.2) |
| N1 | 644 (26.0) |
| N2 | 142 (5.7) |
| N3 | 75 (3.0) |
| Stage | |
| I | 1013 (41.0) |
| II | 1192 (48.2) |
| III | 253 (10.2) |
| IV | 15 (0.6) |
| Pathology (N/A = 17) | |
| IDC | 2214 (90.1) |
| ILC | 123 (5.0) |
| Other | 119 (4.8) |
| Grade (N/A = 54) | |
| I | 528 (21.8) |
| II | 1345 (55.6) |
| III | 546 (22.6) |
| ER (N/A = 16) | |
| Positive | 2035 (82.8) |
| Negative | 422 (17.2) |
| PR (N/A = 17) | |
| Positive | 1815 (73.9) |
| Negative | 641 (26.1) |
| HER-2 (N/A = 82) | |
| Positive | 468 (19.6) |
| Negative | 1923 (80.4) |
| Subtype (N/A = 106) | |
| Luminal A | 932 (39.4) |
| Luminal B1 | 760 (32.1) |
| Luminal B2 | 307 (13.0) |
| HER-2( +) | 176 (7.4) |
| TNBC | 192 (8.1) |
| Ki-67 (N/A = 216) | |
| ≦14 | 942 41.7) |
| > 14 | 1315 (58.3) |
N/A not available, ER estrogen receptor, PR progesterone receptor, HER-2 human epidermal growth factor receptor 2, TNBC triple-negative breast cancer, IDC invasive ductal carcinoma, ILC invasive lobular carcinoma